Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang, China

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 3, 2015, Pages 1690-1695

  Xia, Qiang ^a   Zhao, Li Li ^b,c   Li, Feng ^d   Fan, Yu Mei ^a   Chen, Yuan Yuan ^a   Wu, Bei Bei ^e   Liu, Zheng Wei ^e   Pan, Ai Zhen ^e   Zhu, Min ^a  

^a Zhejiang Prevention and Treatment Center of Tuberculosis   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d SHANGHAI PUBLIC HEALTH CLINICAL CENTER   (China)

^e ZHEJIANG PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; BACTERIAL DNA; BACTERIAL PROTEIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHINA; CODON; DNA SEQUENCE; FEMALE; GENE LOCUS; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; DRUG EFFECTS; GENETICS; MICROBIOLOGY; MIDDLE AGED; PROCEDURES; TUBERCULOSIS, MULTIDRUG-RESISTANT; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CHINA; DNA, BACTERIAL; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; POINT MUTATION; PYRAZINAMIDE; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84923242841     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04541-14     Document Type: Article

References (35)

1. Zhao Y, Xu S, Wang L, Chin DP, Wang S, Jiang G, Xia H, Zhou Y, Li Q, Ou X, Pang Y, Song Y, Zhao B, Zhang H, He G, Guo J, Wang Y. 2012. National survey of drug-resistant tuberculosis in China. N Engl J Med 366:2161-2170. http://dx.doi.org/10.1056/NEJMoa1108789.
2. Heifets L, Lindholm-Levy P. 1992. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis 145:1223-1225. http://dx.doi.org/10.1164/ajrccm/145.5.1223.
3. Scorpio A, Zhang Y. 1996. Mutations in pncA, a gene encoding pyrazinamidase/ nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 2:662-667. http://dx.doi.org/10.1038/nm0696-662.
4. Zhang Y, Mitchison D. 2003. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 7:6-21.
5. Portugal I, Barreiro L, Moniz-Pereira J, Brum L. 2004. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal. Antimicrob Agents Chemother 48:2736-2738. http://dx.doi.org/10.1128/AAC.48.7.2736-2738.2004.
6. Morlock GP, Crawford JT, Butler WR, Brim SE, Sikes D, Mazurek GH, Woodley CL, Cooksey RC. 2000. Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 44:2291-2295. http://dx.doi.org/10.1128/AAC.44.9.2291-2295.2000.
7. Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE, III, Wang H, Zhang W, Zhang Y. 2011. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333:1630-1632. http://dx.doi.org/10.1126/science.1208813.
8. Zhang Y, Permar S, Sun Z. 2002. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 51:42-49.
9. WHO. 2008. Policy guidance on TB drug susceptibility testing (DST) of second-line drugs. WHO/HTM/TB/2008392. WHO, Geneva, Switzerland.
10. Barco P, Cardoso RF, Hirata RD, Leite CQ, Pandolfi JR, Sato DN, Shikama ML, de Melo FF, Mamizuka EM, Campanerut PA, Hirata MH. 2006. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil. J Antimicrob Chemother 58:930-935. http://dx.doi.org/10.1093/jac/dkl363.
11. Somerville W, Thibert L, Schwartzman K, Behr MA. 2005. Extraction of Mycobacterium tuberculosis DNA: a question of containment. J Clin Microbiol 43:2996-2997. http://dx.doi.org/10.1128/JCM.43.6.2996-2997.2005.
12. Brudey K, Driscoll JR, Rigouts L, Prodinger WM, Gori A, Al-Hajoj SA, Allix C, Aristimuno L, Arora J, Baumanis V, Binder L, Cafrune P, Cataldi A, Cheong S, Diel R, Ellermeier C, Evans JT, Fauville-Dufaux M, Ferdinand S, Garcia de Viedma D, Garzelli C, Gazzola L, Gomes HM, Guttierez MC, Hawkey PM, van Helden PD, Kadival GV, Kreiswirth BN, Kremer K, Kubin M, Kulkarni SP, Liens B, Lillebaek T, Ho ML, Martin C, Mokrousov I, Narvskaia O, Ngeow YF, Naumann L, Niemann S, Parwati I, Rahim Z, Rasolofo-Razanamparany V, Rasolonavalona T, Rossetti ML, Rusch-Gerdes S, Sajduda A, Samper S, Shemyakin IG, Singh UB, et al. 2006. Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol 6:23. http://dx.doi.org/10.1186/1471-2180-6-23.
13. Kurbatova EV, Cavanaugh JS, Dalton T, Click ES, Cegielski JP. 2013. Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009. Clin Infect Dis 57:1081-1093. http://dx.doi.org/10.1093/cid/cit452.
14. Jonmalung J, Prammananan T, Leechawengwongs M, Chaiprasert A. 2010. Surveillance of pyrazinamide susceptibility among multidrugresistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. BMC Microbiol 10:223. http://dx.doi.org/10.1186/1471-2180-10-223.
15. Stoffels K, Mathys V, Fauville-Dufaux M, Wintjens R, Bifani P. 2012. Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 56:5186-5193. http://dx.doi.org/10.1128/AAC.05385-11.
16. Simons SO, van Ingen J, van der Laan T, Mulder A, Dekhuijzen PN, Boeree MJ, van Soolingen D. 2012. Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol 50:428-434. http://dx.doi.org/10.1128/JCM.05435-11.
17. Sun Z, Chao Y, Zhang X, Zhang J, Li Y, Qiu Y, Liu Y, Nie L, Guo A, Li C. 2008. Characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates in China. J Clin Microbiol 46:4075-4077. http://dx.doi.org/10.1128/JCM.00822-08.
18. Alexander DC, Ma JH, Guthrie JL, Blair J, Chedore P, Jamieson FB. 2012. Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA. J Clin Microbiol 50:3726-3728. http://dx.doi.org/10.1128/JCM.00620-12.
19. Tan Y, Hu Z, Zhang T, Cai X, Kuang H, Liu Y, Chen J, Yang F, Zhang K, Tan S, Zhao Y. 2014. Role of pncA and rpsA gene sequencing in detection of pyrazinamide resistance in Mycobacterium tuberculosis isolates from southern China. J Clin Microbiol 52:291-297. http://dx.doi.org/10.1128/JCM.01903-13.
20. Miotto P, Cabibbe AM, Feuerriegel S, Casali N, Drobniewski F, Rodionova Y, Bakonyte D, Stakenas P, Pimkina E, Augustynowicz-Kopec E, Degano M, Ambrosi A, Hoffner S, Mansjo M, Werngren J, Rusch-Gerdes S, Niemann S, Cirillo DM. 2014. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. mBio 5:e01819-14. http://dx.doi.org/10.1128/mBio.01819-14.
21. Petrella S, Gelus-Ziental N, Maudry A, Laurans C, Boudjelloul R, Sougakoff W. 2011. Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: insights into natural and acquired resistance to pyrazinamide. PLoS One 6:e15785. http://dx.doi.org/10.1371/journal.pone.0015785.
22. Zhang H, Deng JY, Bi LJ, Zhou YF, Zhang ZP, Zhang CG, Zhang Y, Zhang XE. 2008. Characterization of Mycobacterium tuberculosis nicotinamidase/ pyrazinamidase. FEBS J 275:753-762. http://dx.doi.org/10.1111/j.1742-4658.2007.06241.x.
23. Napiórkowska A, Rüsch-Gerdes S, Hillemann D, Richter E, Augustynowicz-Kopeć E. 2014. Characterisation of pyrazinamide-resistant Mycobacterium tuberculosis strains isolated in Poland and Germany. Int J Tuberc Lung Dis 18:454-460. http://dx.doi.org/10.5588/ijtld.13.0457.
24. Mphahlele M, Syre H, Valvatne H, Stavrum R, Mannsaker T, Muthivhi T, Weyer K, Fourie PB, Grewal HM. 2008. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol 46:3459-3464. http://dx.doi.org/10.1128/JCM.00973-08.
25. Juréen P, Werngren J, Toro JC, Hoffner S. 2008. Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother 52:1852-1854. http://dx.doi.org/10.1128/AAC.00110-08.
26. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE. 2011. Molecular detection of mutations associated with first-and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 55:2032-2041. http://dx.doi.org/10.1128/AAC.01550-10.
27. Sheen P, Mendez M, Gilman RH, Pena L, Caviedes L, Zimic MJ, Zhang Y, Moore DA, Evans CA. 2009. Sputum PCR-single-strand conformational polymorphism test for same-day detection of pyrazinamide resistance in tuberculosis patients. J Clin Microbiol 47:2937-2943. http://dx.doi.org/10.1128/JCM.01594-08.
28. Feuerriegel S, Oberhauser B, George AG, Dafae F, Richter E, Rusch-Gerdes S, Niemann S. 2012. Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a highincidence setting. BMC Microbiol 12:90. http://dx.doi.org/10.1186/1471-2180-12-90.
29. Doustdar F, Khosravi AD, Farnia P. 2009. Mycobacterium tuberculosis genotypic diversity in pyrazinamide-resistant isolates of Iran. Microb Drug Resist 15:251-256. http://dx.doi.org/10.1089/mdr.2009.0066.
30. Zhao LL, Chen Y, Chen ZN, Liu HC, Hu PL, Sun Q, Zhao XQ, Jiang Y, Li GL, Tan YH, Wan KL. 2014. Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Hunan, China. Antimicrob Agents Chemother 58:3475-3480. http://dx.doi.org/10.1128/AAC.02426-14.
31. Kim HJ, Kwak HK, Lee J, Yun YJ, Lee JS, Lee MS, Min SY, Park SK, Kang HS, Maeng YH, Kim SY, Kim SY, Kook YH, Kim YR, Lee KH. 2012. Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea. Int J Tuberc Lung Dis 16: 98-103. http://dx.doi.org/10.5588/ijtld.10.0739.
32. Simons SO, van der Laan T, Mulder A, van Ingen J, Rigouts L, Dekhuijzen PN, Boeree MJ, van Soolingen D. 2014. Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm. Clin Microbiol Infect 20:1015-1020. http://dx.doi.org/10.1111/1469-0691.12696.
33. Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F. 2010. Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol 48:300-301. http://dx.doi.org/10.1128/JCM.01775-09.
34. Chang KC, Yew WW, Zhang Y. 2011. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob Agents Chemother 55:4499-4505. http://dx.doi.org/10.1128/AAC.00630-11.
35. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. 1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 35: 907-914.